ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19

NCT04583956 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

214

Enrollment

NIH

Sponsor class

Conditions

COVID-19

Interventions

OTHER: Placebo
DRUG: Remdesivir
BIOLOGICAL: Risankizumab

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)